Oral Antibiotic for Pediatric Bronchopneumonia with Penicillin Allergy
Azithromycin is the recommended oral antibiotic for a child with bronchopneumonia who is allergic to penicillin, dosed at 10 mg/kg on day 1 (maximum 500 mg), followed by 5 mg/kg once daily on days 2-5 (maximum 250 mg/day). 1, 2, 3
Primary Recommendation
Azithromycin is the first-line treatment for penicillin-allergic children with community-acquired pneumonia, providing excellent coverage for both typical bacterial pathogens (Streptococcus pneumoniae) and atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae). 1, 3
The standard 5-day course consists of 10 mg/kg on day 1 (maximum 500 mg), then 5 mg/kg/day on days 2-5 (maximum 250 mg/day). 1, 4
This macrolide is FDA-approved for community-acquired pneumonia in children caused by C. pneumoniae, H. influenzae, M. pneumoniae, and S. pneumoniae. 4
Alternative Options for Non-Serious Penicillin Allergy
If the penicillin allergy is non-serious (not anaphylaxis or severe reaction), oral cephalosporins are preferred alternatives including cefpodoxime, cefprozil, or cefuroxime, provided under medical supervision. 2, 3
Second-generation cephalosporins like cefuroxime axetil (20-50 mg/kg/day divided twice daily, maximum 500 mg/dose) offer strong pneumococcal coverage. 5
Cefaclor (20-40 mg/kg/day divided three times daily, maximum 1000 mg/day) is another acceptable second-generation option. 5
Severe Penicillin Allergy Considerations
For serious penicillin allergy (anaphylaxis, Stevens-Johnson syndrome), azithromycin remains the drug of choice as cephalosporins carry cross-reactivity risk. 3
In severe cases requiring hospitalization with serious penicillin allergy, levofloxacin (8-10 mg/kg/dose once daily for children ≥5 years, maximum 750 mg/day) or linezolid (30 mg/kg/day divided three times daily for children <12 years, maximum 600 mg/dose) can be considered. 5
Critical Pitfalls to Avoid
Macrolide monotherapy should be used with caution in severe pneumococcal disease due to potential for secondary sites of infection, including meningitis, particularly given rising macrolide resistance rates. 3, 6
Macrolide resistance in S. pneumoniae ranges from 0-15% in Europe and the USA but can reach 30% in Israel and up to 90-100% in Asia, which may lead to treatment failure. 6
Do not underdose azithromycin—the weight-based dosing is critical for efficacy, and the full 5-day course must be completed. 3
Hospitalization Criteria
Hospitalize if oxygen saturation ≤92% on room air, respiratory rate >50 breaths/min, difficulty breathing or grunting, signs of dehydration, or inability to take oral medications. 1, 3
Children younger than 6 months should be hospitalized for inpatient care regardless of severity. 5
For hospitalized penicillin-allergic patients, intravenous azithromycin 10 mg/kg on days 1 and 2, then transition to oral therapy is recommended. 1, 3
Reassessment and Treatment Failure
Clinical improvement should be assessed within 48-72 hours of starting therapy. 1, 3
Treatment failure may indicate resistant organisms (particularly macrolide-resistant pneumococcus), inadequate dosing, poor compliance, complications like empyema, or alternative diagnosis. 1
If no improvement occurs by 48-72 hours, consider switching to a fluoroquinolone (levofloxacin) or adding vancomycin/clindamycin if MRSA is suspected. 1, 3